TY - JOUR
T1 - Next-Generation Sequencing in Clinical Microbiology
T2 - Are We There Yet?
AU - Mitchell, Stephanie L.
AU - Simner, Patricia J.
N1 - Funding Information:
Disclosure Statement: P.J. Simner reports grants and personal fees from Accelerate Diagnostics , grants from BD Diagnostics, Inc , grants from bioMerieux, Inc , grants from Check-Points Diagnostics, BV , grants from Hardy Diagnostics , personal fees from Roche Diagnostics, personal fees from Opgen Inc, personal fees from CosmosID, outside the submitted work. P.J. Simner reports travel funds from Oxford Nanopore Technologies . S.L. Mitchell is a member of GenMark Diagnostic’s Scientific Advisory Board.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/9
Y1 - 2019/9
N2 - Next-generation sequencing (NGS) applications have been transitioning from research tools to diagnostic methods and are becoming more commonplace in clinical microbiology laboratories. These applications include (1) whole-genome sequencing, (2) targeted next-generation sequencing methods, and (3) metagenomic next-generation sequencing. The introduction of these methods into the clinical microbiology laboratory has led to the theoretic question of “Will NGS-based methods supplant traditional methods for strain typing, identification, and antimicrobial susceptibility prediction?” The authors address this question and discuss where we are at now with clinical NGS applications for infectious diseases, what does the future hold, and at what cost?
AB - Next-generation sequencing (NGS) applications have been transitioning from research tools to diagnostic methods and are becoming more commonplace in clinical microbiology laboratories. These applications include (1) whole-genome sequencing, (2) targeted next-generation sequencing methods, and (3) metagenomic next-generation sequencing. The introduction of these methods into the clinical microbiology laboratory has led to the theoretic question of “Will NGS-based methods supplant traditional methods for strain typing, identification, and antimicrobial susceptibility prediction?” The authors address this question and discuss where we are at now with clinical NGS applications for infectious diseases, what does the future hold, and at what cost?
KW - Clinical microbiology
KW - Infectious disease
KW - Metagenomics next-generations sequencing (mNGS)
KW - Next-generation sequencing (NGS)
KW - Targeted next-generation sequencing (tNGS)
KW - Whole-genome sequencing (WGS)
UR - http://www.scopus.com/inward/record.url?scp=85071154352&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071154352&partnerID=8YFLogxK
U2 - 10.1016/j.cll.2019.05.003
DO - 10.1016/j.cll.2019.05.003
M3 - Review article
C2 - 31383265
AN - SCOPUS:85071154352
SN - 0272-2712
VL - 39
SP - 405
EP - 418
JO - Clinics in laboratory medicine
JF - Clinics in laboratory medicine
IS - 3
ER -